MichaelThomasSchweizerMD

Oncology • Seattle, WA

Genitourinary Oncology, Hematologic Oncology

Associate Professor of Medicine, University of Washington

Join to view full profile

Dr. Schweizer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schweizer's full profile

Already have an account?

Office
825 Eastlake Ave E

Seattle, WA 98109
Phone+1 206-288-1000

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
University of ChicagoResidency, Internal Medicine, 2008 - 2011
Lewis Katz School of Medicine at Temple UniversityClass of 2008

Certifications & Licensure

AK State Medical License 2022 - 2025
WA State Medical License 2014 - 2025
MD State Medical License 2011 - 2015
IL State Medical License 2008 - 2011
American Board of Internal Medicine Medical Oncology

Clinical Trials

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Start of enrollment: 2020 Apr 27
Terminated
Phase 2
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Start of enrollment: 2020 Feb 06
Active, not recruiting
Phase 3
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2019 Nov 22
Terminated
Phase 1
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load Start of enrollment: 2021 Apr 13
Active, not recruiting
Phase 2
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2021 Jan 20
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who ReceivedLu-PSMA-617: Importance ofF-FDG-...
Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S Nelson
Journal of Nuclear Medicine. 2025-01-03
1 citations
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer ReceivingLu-PSMA-617.
Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, Todd Yezefski, Michael C Haffner
Journal of Nuclear Medicine. 2024-12-03
A Multicenter Evaluation of Treatment-associated Changes in Body Composition in Men With Germ Cell Tumors of the Testis: Implications for Adverse Events and Complicati...
Claire Buxton, Benjamin N Schmeusser, Sarah K Holt, Dattatraya Patil, Anthea Phuong
Urology. 2024-10-01

Journal Articles

Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing Interference
Michael T Schweizer, Petros Grivas, Heather H Cheng, Evan Y Yu, JAMA Oncology

Lectures

Genomic characterization of ductal adenocarcinoma of the prostate.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Fred Hutch at ASCO: Progress in Treating Metastatic Cancer, Hospice Access for Cancer Patients, Use of Machine Learning with CAR T-cell TherapyMay 23rd, 2024
Madison Vaccines Incorporated Expands Clinical Trial of MVI-118 for Prostate Cancer to University of WashingtonMarch 21st, 2017
Bipolar Androgen Therapy Promising for Advanced HormoneSensitive PCaJanuary 5th, 2016
Join now to see all